二氧化钛纳米管及其作为溶栓药物载体的研究

Preparation of TiO_(2) nanotubes and their application as carriers for thrombolytic drugs

为改善直接使用溶栓蛋白药物尿激酶(uPA)时容易形成全身性纤维原蛋白分解和大出血的问题,设计并制备了负载溶栓药物的二氧化钛纳米管支架.采用阳极氧化法合成排列整齐有序的二氧化钛纳米管阵列,该纳米管可负载溶栓药物uPA,通过酰胺键将壳聚糖(CS)连接到二氧化钛纳米管阵列上,可对纳米管进行封端,得到uPA缓控释放的溶栓支架Ti-TNTs-uPA-CS.用扫描电子显微镜、红外光谱等方法对Ti-TNTs-uPA-CS的形貌和结构进行表征,并模拟人体生理环境进行体外溶栓实验.与空白组对比后的结果表明,Ti-TNTs-uPA-CS具有良好的溶栓效果,并随着溶栓时间积累,溶栓效果显现,说明该溶栓支架对血栓的治疗具有积极意义.

In order to solve the problems of direct use of urokinase(uPA)(e.g.the risk of breakdown systemic fibrinogen and bleeding)and improve the thrombolytic effect,TiO_(2) nanotube arrays were designed and prepared as thrombolytic drug scaffold.The TiO_(2) nanotube arrays were synthesized by anodized electrochemical method.The thrombolytic drug uPA could be encapsulated into the TiO_(2) nanotube arrays,and chitosan(CS)was used as capping agent to combine in the tubes through amide bonds.The morphology and structure of Ti-TNTs-uPA-CS were proved by scanning electron microscopy and infrared spectroscopy.In vitro thrombolytic experiments were performed to simulate human physiological environment.The results showed that Ti-TNTs-uPA-CS produced good thrombolytic ability,compared to PBS control group.It indicates the potential promise of the TiO_(2) nanotube arrays for uPA encapsulation and thrombus treatment.